Skip to main content
. Author manuscript; available in PMC: 2010 Oct 15.
Published in final edited form as: J Immunol. 2009 Sep 28;183(8):5407–5417. doi: 10.4049/jimmunol.0901760

FIGURE 5.

FIGURE 5

HMBPP/IL-2 cotreatment increases phosphoantigen-specific Vγ2 T cells during acute SHIV infection and circulating TNF- α and IFN- γ during chronic infection. Percentages of CD3+ cells that are Vγ2+TNF-α+ after ex vivo HMBPP restimulation are shown over time (a and b). Arrows indicate the time when treatment was given. Plasma IFN- γ and TNF-α concentrations are shown upon treatment during chronic infection (c and d). Data for individual animals treated with HMBPP plus IL-2, IL-2 alone, or sham only during chronic infection (a and c) or during both acute and chronic infection (b and d) are shown. Horizontal lines indicate detection limits (c and d). The increases in IFN- γ(p = 0.015) and TNF- α (p = 0.0024) after HMBPP plus IL-2 treatment are statistically different from pretreatment (c and d).